APO Research
Talk to an analyst

APO RESEARCH · REPORT

Acute Hepatic Porphyria Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Acute Hepatic Porphyria Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026179 pages

Choose your research edition.

Industry ResearchAcute Hepatic Porphyria Drug Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Hepatic Porphyria Drug Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Acute Hepatic Porphyria Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Hepatic Porphyria Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Hepatic Porphyria Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Acute Hepatic Porphyria Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Acute Hepatic Porphyria Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Acute Hepatic Porphyria Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Acute Hepatic Porphyria Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Acute Hepatic Porphyria Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Acute Hepatic Porphyria Drug include Alnylam Pharmaceuticals and Recordati Rare Diseases among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Acute Hepatic Porphyria Drug market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Acute Hepatic Porphyria Drug and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Acute Hepatic Porphyria Drug revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Acute Hepatic Porphyria Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Acute Hepatic Porphyria Drug Segment by Company

Alnylam Pharmaceuticals

Recordati Rare Diseases

Acute Hepatic Porphyria Drug Segment by Type

350 Mg

313 Mg

Acute Hepatic Porphyria Drug Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Others

Acute Hepatic Porphyria Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Hepatic Porphyria Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Hepatic Porphyria Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Hepatic Porphyria Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Acute Hepatic Porphyria Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Acute Hepatic Porphyria Drug industry.

Chapter 3: Detailed analysis of Acute Hepatic Porphyria Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Acute Hepatic Porphyria Drugrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Acute Hepatic Porphyria Drug Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of 350 Mg Table 3. Key Players of 313 Mg Table 4. Global Acute Hepatic Porphyria Drug Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Retail Pharmacy Table 6. Key Players of Online Pharmacy Table 7. Key Players of Hospital Pharmacy Table 8. Key Players of Others Table 9. Global Acute Hepatic Porphyria Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Acute Hepatic Porphyria Drug Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Acute Hepatic Porphyria Drug Market Share by Region (2021-2026) Table 12. Global Acute Hepatic Porphyria Drug Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Acute Hepatic Porphyria Drug Market Share by Region (2027-2032) Table 14. Acute Hepatic Porphyria Drug Industry Trends Table 15. Acute Hepatic Porphyria Drug Industry Drivers Table 16. Acute Hepatic Porphyria Drug Industry Opportunities and Challenges Table 17. Acute Hepatic Porphyria Drug Industry Restraints Table 18. Global Acute Hepatic Porphyria Drug Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Acute Hepatic Porphyria Drug Revenue Market Share by Company (2021-2026) Table 20. Global Acute Hepatic Porphyria Drug Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Acute Hepatic Porphyria Drug Key Company Head Office and Area Served Table 22. Global Acute Hepatic Porphyria Drug Company, Product Type & Application Table 23. Global Acute Hepatic Porphyria Drug Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Acute Hepatic Porphyria Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Acute Hepatic Porphyria Drug Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Acute Hepatic Porphyria Drug Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Acute Hepatic Porphyria Drug Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Acute Hepatic Porphyria Drug Revenue Market Share by Type (2021-2026) Table 30. Global Acute Hepatic Porphyria Drug Revenue Market Share by Type (2027-2032) Table 31. Global Acute Hepatic Porphyria Drug Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Acute Hepatic Porphyria Drug Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Acute Hepatic Porphyria Drug Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Acute Hepatic Porphyria Drug Revenue Market Share by Application (2021-2026) Table 35. Global Acute Hepatic Porphyria Drug Revenue Market Share by Application (2027-2032) Table 36. Alnylam Pharmaceuticals Company Information Table 37. Alnylam Pharmaceuticals Business Overview Table 38. Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Product Portfolio Table 40. Alnylam Pharmaceuticals Recent Development Table 41. Recordati Rare Diseases Company Information Table 42. Recordati Rare Diseases Business Overview Table 43. Recordati Rare Diseases Acute Hepatic Porphyria Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Recordati Rare Diseases Acute Hepatic Porphyria Drug Product Portfolio Table 45. Recordati Rare Diseases Recent Development Table 46. North America Acute Hepatic Porphyria Drug Market Size by Type (2021-2026) & (US$ Million) Table 47. North America Acute Hepatic Porphyria Drug Market Size by Type (2027-2032) & (US$ Million) Table 48. North America Acute Hepatic Porphyria Drug Market Size by Application (2021-2026) & (US$ Million) Table 49. North America Acute Hepatic Porphyria Drug Market Size by Application (2027-2032) & (US$ Million) Table 50. North America Acute Hepatic Porphyria Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 51. North America Acute Hepatic Porphyria Drug Market Size by Country (2021-2026) Table 52. North America Acute Hepatic Porphyria Drug Market Size by Country (2027-2032) Table 53. Europe Acute Hepatic Porphyria Drug Market Size by Type (2021-2026) & (US$ Million) Table 54. Europe Acute Hepatic Porphyria Drug Market Size by Type (2027-2032) & (US$ Million) Table 55. Europe Acute Hepatic Porphyria Drug Market Size by Application (2021-2026) & (US$ Million) Table 56. Europe Acute Hepatic Porphyria Drug Market Size by Application (2027-2032) & (US$ Million) Table 57. Europe Acute Hepatic Porphyria Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 58. Europe Acute Hepatic Porphyria Drug Market Size by Country (2021-2026) Table 59. Europe Acute Hepatic Porphyria Drug Market Size by Country (2027-2032) Table 60. China Acute Hepatic Porphyria Drug Market Size by Type (2021-2026) & (US$ Million) Table 61. China Acute Hepatic Porphyria Drug Market Size by Type (2027-2032) & (US$ Million) Table 62. China Acute Hepatic Porphyria Drug Market Size by Application (2021-2026) & (US$ Million) Table 63. China Acute Hepatic Porphyria Drug Market Size by Application (2027-2032) & (US$ Million) Table 64. Asia Acute Hepatic Porphyria Drug Market Size by Type (2021-2026) & (US$ Million) Table 65. Asia Acute Hepatic Porphyria Drug Market Size by Type (2027-2032) & (US$ Million) Table 66. Asia Acute Hepatic Porphyria Drug Market Size by Application (2021-2026) & (US$ Million) Table 67. Asia Acute Hepatic Porphyria Drug Market Size by Application (2027-2032) & (US$ Million) Table 68. Asia Acute Hepatic Porphyria Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 69. Asia Acute Hepatic Porphyria Drug Market Size by Country (2021-2026) Table 70. Asia Acute Hepatic Porphyria Drug Market Size by Country (2027-2032) Table 71. South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Type (2021-2026) & (US$ Million) Table 72. South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Type (2027-2032) & (US$ Million) Table 73. South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Application (2021-2026) & (US$ Million) Table 74. South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Application (2027-2032) & (US$ Million) Table 75. South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 76. South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Country (2021-2026) Table 77. South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Country (2027-2032) Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. Acute Hepatic Porphyria Drug Product Image Figure 2. Global Acute Hepatic Porphyria Drug Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Acute Hepatic Porphyria Drug Market Share by Type: 2025 VS 2032 Figure 4. 350 Mg Image Figure 5. 313 Mg Image Figure 6. Global Acute Hepatic Porphyria Drug Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Acute Hepatic Porphyria Drug Market Share by Application: 2025 VS 2032 Figure 8. Retail Pharmacy Image Figure 9. Online Pharmacy Image Figure 10. Hospital Pharmacy Image Figure 11. Others Image Figure 12. Global Acute Hepatic Porphyria Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 14. Global Acute Hepatic Porphyria Drug Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global Acute Hepatic Porphyria Drug Market Share by Players in 2025 Figure 17. Global Top 5 and 10 Acute Hepatic Porphyria Drug Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Acute Hepatic Porphyria Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Acute Hepatic Porphyria Drug Revenue Market Share by Type (2021-2032) Figure 21. Global Acute Hepatic Porphyria Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Acute Hepatic Porphyria Drug Revenue Market Share by Application (2021-2032) Figure 23. North America Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 24. North America Acute Hepatic Porphyria Drug Market Share by Type (2021-2032) Figure 25. North America Acute Hepatic Porphyria Drug Market Share by Application (2021-2032) Figure 26. North America Acute Hepatic Porphyria Drug Market Share by Country (2021-2032) Figure 27. United States Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 28. Canada Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 29. Mexico Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 30. Europe Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 31. Europe Acute Hepatic Porphyria Drug Market Share by Type (2021-2032) Figure 32. Europe Acute Hepatic Porphyria Drug Market Share by Application (2021-2032) Figure 33. Europe Acute Hepatic Porphyria Drug Market Share by Country (2021-2032) Figure 34. Germany Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 35. France Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 36. U.K. Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 37. Italy Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 38. Russia Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 40. China Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 41. China Acute Hepatic Porphyria Drug Market Share by Type (2021-2032) Figure 42. China Acute Hepatic Porphyria Drug Market Share by Application (2021-2032) Figure 43. Asia Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 44. Asia Acute Hepatic Porphyria Drug Market Share by Type (2021-2032) Figure 45. Asia Acute Hepatic Porphyria Drug Market Share by Application (2021-2032) Figure 46. Asia Acute Hepatic Porphyria Drug Market Share by Country (2021-2032) Figure 47. Japan Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 48. South Korea Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 51. India Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 52. Australia Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Share by Country (2021-2032) Figure 57. Brazil Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 58. South Africa Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 60. Turkey Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 61. Argentina Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 62. UAE Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 63. Egypt Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 64. Chile Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • 350 Mg
  • 313 Mg
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
  • Others
Companies covered
  • Alnylam Pharmaceuticals
  • Recordati Rare Diseases

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Acute Hepatic Porphyria Drug Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 350 Mg
  5. 1.2.3 313 Mg
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Acute Hepatic Porphyria Drug Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Retail Pharmacy
  9. 1.3.3 Online Pharmacy
  10. 1.3.4 Hospital Pharmacy
  11. 1.3.5 Others
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global Acute Hepatic Porphyria Drug Growth Trends by Region
  14. 1.5.1 Global Acute Hepatic Porphyria Drug Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 Acute Hepatic Porphyria Drug Market Size by Region (2021-2026)
  16. 1.5.3 Acute Hepatic Porphyria Drug Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global Acute Hepatic Porphyria Drug Market Dynamics
  1. 2.1 Acute Hepatic Porphyria Drug Industry Trends
  2. 2.2 Acute Hepatic Porphyria Drug Industry Drivers
  3. 2.3 Acute Hepatic Porphyria Drug Industry Opportunities and Challenges
  4. 2.4 Acute Hepatic Porphyria Drug Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Acute Hepatic Porphyria Drug Revenue by Company (2021-2026)
  2. 3.2 Global Acute Hepatic Porphyria Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Acute Hepatic Porphyria Drug Key Company Head office and Area Served
  4. 3.4 Global Acute Hepatic Porphyria Drug Company, Product Type & Application
  5. 3.5 Global Acute Hepatic Porphyria Drug Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Acute Hepatic Porphyria Drug Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Acute Hepatic Porphyria Drug Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Acute Hepatic Porphyria Drug Tier 1, Tier 2, and Tier 3
4 Acute Hepatic Porphyria Drug Market by Type
  1. 4.1 Global Acute Hepatic Porphyria Drug Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Acute Hepatic Porphyria Drug Market Size by Type (2021-2032)
  3. 4.3 Global Acute Hepatic Porphyria Drug Market Size Share by Type (2021-2032)
5 Acute Hepatic Porphyria Drug Market by Application
  1. 5.1 Global Acute Hepatic Porphyria Drug Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Acute Hepatic Porphyria Drug Market Size by Application (2021-2032)
  3. 5.3 Global Acute Hepatic Porphyria Drug Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Alnylam Pharmaceuticals
  2. 6.1.1 Alnylam Pharmaceuticals Company Information
  3. 6.1.2 Alnylam Pharmaceuticals Business Overview
  4. 6.1.3 Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Product Portfolio
  6. 6.1.5 Alnylam Pharmaceuticals Recent Developments
  7. 6.2 Recordati Rare Diseases
  8. 6.2.1 Recordati Rare Diseases Company Information
  9. 6.2.2 Recordati Rare Diseases Business Overview
  10. 6.2.3 Recordati Rare Diseases Acute Hepatic Porphyria Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Recordati Rare Diseases Acute Hepatic Porphyria Drug Product Portfolio
  12. 6.2.5 Recordati Rare Diseases Recent Developments
7 North America
  1. 7.1 North America Acute Hepatic Porphyria Drug Market Size (2021-2032)
  2. 7.2 North America Acute Hepatic Porphyria Drug Market Size by Type
  3. 7.2.1 North America Acute Hepatic Porphyria Drug Market Size by Type (2021-2026)
  4. 7.2.2 North America Acute Hepatic Porphyria Drug Market Size by Type (2027-2032)
  5. 7.2.3 North America Acute Hepatic Porphyria Drug Market Share by Type (2021-2032)
  6. 7.3 North America Acute Hepatic Porphyria Drug Market Size by Application
  7. 7.3.1 North America Acute Hepatic Porphyria Drug Market Size by Application (2021-2026)
  8. 7.3.2 North America Acute Hepatic Porphyria Drug Market Size by Application (2027-2032)
  9. 7.3.3 North America Acute Hepatic Porphyria Drug Market Share by Application (2021-2032)
  10. 7.4 North America Acute Hepatic Porphyria Drug Market Size by Country
  11. 7.4.1 North America Acute Hepatic Porphyria Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Acute Hepatic Porphyria Drug Market Size by Country (2021-2026)
  13. 7.4.3 North America Acute Hepatic Porphyria Drug Market Size by Country (2027-2032)
  14. 7.4.4 North America Acute Hepatic Porphyria Drug Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Acute Hepatic Porphyria Drug Market Size (2021-2032)
  2. 8.2 Europe Acute Hepatic Porphyria Drug Market Size by Type
  3. 8.2.1 Europe Acute Hepatic Porphyria Drug Market Size by Type (2021-2026)
  4. 8.2.2 Europe Acute Hepatic Porphyria Drug Market Size by Type (2027-2032)
  5. 8.2.3 Europe Acute Hepatic Porphyria Drug Market Share by Type (2021-2032)
  6. 8.3 Europe Acute Hepatic Porphyria Drug Market Size by Application
  7. 8.3.1 Europe Acute Hepatic Porphyria Drug Market Size by Application (2021-2026)
  8. 8.3.2 Europe Acute Hepatic Porphyria Drug Market Size by Application (2027-2032)
  9. 8.3.3 Europe Acute Hepatic Porphyria Drug Market Share by Application (2021-2032)
  10. 8.4 Europe Acute Hepatic Porphyria Drug Market Size by Country
  11. 8.4.1 Europe Acute Hepatic Porphyria Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Acute Hepatic Porphyria Drug Market Size by Country (2021-2026)
  13. 8.4.3 Europe Acute Hepatic Porphyria Drug Market Size by Country (2027-2032)
  14. 8.4.4 Europe Acute Hepatic Porphyria Drug Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Acute Hepatic Porphyria Drug Market Size (2021-2032)
  2. 9.2 China Acute Hepatic Porphyria Drug Market Size by Type
  3. 9.2.1 China Acute Hepatic Porphyria Drug Market Size by Type (2021-2026)
  4. 9.2.2 China Acute Hepatic Porphyria Drug Market Size by Type (2027-2032)
  5. 9.2.3 China Acute Hepatic Porphyria Drug Market Share by Type (2021-2032)
  6. 9.3 China Acute Hepatic Porphyria Drug Market Size by Application
  7. 9.3.1 China Acute Hepatic Porphyria Drug Market Size by Application (2021-2026)
  8. 9.3.2 China Acute Hepatic Porphyria Drug Market Size by Application (2027-2032)
  9. 9.3.3 China Acute Hepatic Porphyria Drug Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Acute Hepatic Porphyria Drug Market Size (2021-2032)
  2. 10.2 Asia Acute Hepatic Porphyria Drug Market Size by Type
  3. 10.2.1 Asia Acute Hepatic Porphyria Drug Market Size by Type (2021-2026)
  4. 10.2.2 Asia Acute Hepatic Porphyria Drug Market Size by Type (2027-2032)
  5. 10.2.3 Asia Acute Hepatic Porphyria Drug Market Share by Type (2021-2032)
  6. 10.3 Asia Acute Hepatic Porphyria Drug Market Size by Application
  7. 10.3.1 Asia Acute Hepatic Porphyria Drug Market Size by Application (2021-2026)
  8. 10.3.2 Asia Acute Hepatic Porphyria Drug Market Size by Application (2027-2032)
  9. 10.3.3 Asia Acute Hepatic Porphyria Drug Market Share by Application (2021-2032)
  10. 10.4 Asia Acute Hepatic Porphyria Drug Market Size by Country
  11. 10.4.1 Asia Acute Hepatic Porphyria Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Acute Hepatic Porphyria Drug Market Size by Country (2021-2026)
  13. 10.4.3 Asia Acute Hepatic Porphyria Drug Market Size by Country (2027-2032)
  14. 10.4.4 Asia Acute Hepatic Porphyria Drug Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Acute Hepatic Porphyria Drug Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst